AMGN's Quality Score rose 2 points on Fri, Oct 30, to 21.
Follow AMGN's trial news. Pro members can get an alert when Amgen files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 160% over five years while the S&P 500 rose 76%.
“Total product sales increased 10% in 2025, driven by volume growth of 13%, partially offset by declines in net selling price of 3%.”
| The company | Gross margin up 5 points |
| Latest filing | 8-K, Oct 27 |
ReportReports tomorrow, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 3 of its last 4 reports, +4.0% on average. Past reports ›
Fri Nov 6: American College of Rheumatology…Industry event · date confirmed.
2 more dates ahead: the conference and dividend dates, for Pro members.
After its last 4 reports it closed +4.0% on average, higher 3 of 4 times.
An officer, Rachna Khosla, sold 3,252 shares on Aug 13. 5 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Exceptionalfor quality, not price, 7 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. AMGN scores 21 today, against a median of 15.5 over its last 20 recorded sessions.
AMGN is #4 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 4 |
Net income over four quarters: AMGN $8.74B, GILD -$3.24B.
Reports Tue Nov 3, after the close (tomorrow). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“Non-GAAP EPS increased 4% from $6.02 to $6.29 for the second quarter, primarily driven by higher revenues, partially offset by higher operating expenses and higher income tax expense.”
AMGN's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total revenues | $38.2B to $39.4B |
“GAAP earnings per share (EPS) increased 65% from $2.65 to $4.37 for the second quarter, driven by higher revenues.”
From its results filing (SEC filing · Aug 4)
Sales grew 7.6% a year over 5 years, fiscal 2020 to 2025.
Pays $10.08 a share a year.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 4, 2026 | +0.9% | +4.6% | +6.2% |
| Apr 30, 2026 | -4.0% | -4.8% | -5.0% |
| Feb 3, 2026 | +4.0% | +8.2% | +7.7% |
Sales grew every year from 2019 to 2025, to $37B. It made a profit in each of the seven years.
Its dividends come to 54% of its free cash flow.
| Dividend | $10.08 a share a year |
| Paid out | About $5.5B a year |
| Free cash flow | $10B |
| Record | Raised each of the last 5 years |
3 insiders sold $4.1M across 6 filings in the last 6 months. No open-market buys on record. The newest:
26 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: AMGN is 4.9% of SCHD, 1.5% of DGRO, and 1.2% of QQQI, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
“We operate in a highly competitive environment.”
AMGN scores 21 today, which Breakaway calls Exceptional. It is #4 of 291 in Biotech by Quality Score, with 7 of 14 chart checks firing. Up 160% over five years while the S&P 500 rose 76%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
AMGN scores 21 today, which Breakaway calls Exceptional (20 or more). That is #4 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AMGN's 21.
3 insiders sold $4.1M across 6 filings in the last 6 months. No open-market buys on record. The newest is Rachna Khosla, SVP, Business Development, who sold $825K on Aug 11. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.